Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
Patients who underwent robotic liver resection had shorter hospital stays and were less likely to be admitted to the ICU than patients who underwent open liver resection.
Hepatocellular Carcinoma
SBRT Proposed as Standard Treatment Option for Advanced Hepatocellular Carcinoma
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
Imjudo Plus Imfinzi Approved for Unresectable Hepatocellular Carcinoma
The FDA has approved Imjudo (tremelimumab) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.
First-Line Pembrolizumab Failed to Improve PFS, OS in Advanced HCC
Adding pembrolizumab to lenvatinib does not improve outcomes in patients with advanced hepatocellular carcinoma, results of the LEAP-002 study suggest.
Tislelizumab Deemed Noninferior to Sorafenib in Unresectable Hepatocellular Carcinoma
Final results from the RATIONALE-301 trial suggest tislelizumab is noninferior to sorafenib for first-line treatment of unresectable hepatocellular carcinoma.
Camrelizumab Plus Rivoceranib: A New First-Line Option for Unresectable Hepatocellular Carcinoma
Camrelizumab plus rivoceranib produced the longest overall survival seen to date in a frontline pivotal phase 3 study of advanced hepatocellular carcinoma, according to researchers.
Immune Checkpoint Inhibitor Therapy Linked With Improved Quality of Life
Immune checkpoint inhibitor therapy appears to maintain or improve quality of life in patients with solid tumor malignancies.
Most Patients With Cirrhosis Do Not Undergo Hepatocellular Carcinoma Surveillance
Researchers found that hepatocellular carcinoma surveillance was underutilized in approximately 80% of patients with cirrhosis.
TACE Prolongs PFS and OS in Advanced Hepatocellular Carcinoma
Combining transarterial chemoembolization with lenvatinib can improve survival in patients with advanced hepatocellular carcinoma.
ICIs Appear Safer Than TKIs for Advanced Hepatocellular Carcinoma
A meta-analysis suggests that immune checkpoint inhibitors are safer than tyrosine kinase inhibitors as neoadjuvant therapy for advanced hepatocellular carcinoma.
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...